Combined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice.
OBJECTIVE
To investigate the effects of drugs known to elevate adenosine 3':5'-cyclic monophosphate (cAMP) on experimental amyloidosis.


METHODS
A beta 2-agonist, terbutaline, and a phosphodiesterase inhibitor, aminophylline, were administered in combination in a mouse model of amyloidosis induced by inflammatory stimulation with silver nitrate. Amyloidosis was quantitated by radioimmunoassay for splenic amyloid A (AA) protein.


RESULTS
At the doses selected, aminophylline/terbutaline inhibited splenic amyloid deposition more potently than did colchicine, a known inhibitor of amyloidosis.


CONCLUSIONS
Drugs known to elevate cAMP inhibit experimental mouse AA amyloidosis.
Brandwein
S R
SR
Rush Medical College, Chicago, Illinois.
Sipe
J D
JD
Cohen
A S
AS
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000628:Aminophylline / Q000627:therapeutic use*; D000686:Amyloidosis / Q000517:prevention & control*; D000818:Animals; D000242:Cyclic AMP / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D008808:Mice, Inbred CBA; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010865:Pilot Projects; D000685:Serum Amyloid A Protein / Q000032:analysis; D013154:Spleen / Q000737:chemistry; D013726:Terbutaline / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D010726:Phosphodiesterase Inhibitors; D000685:Serum Amyloid A Protein; D000628:Aminophylline; D000242:Cyclic AMP; D013726:Terbutaline